<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747977</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-DED-2020-201</org_study_id>
    <nct_id>NCT04747977</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease</brief_title>
  <official_title>A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and&#xD;
      symptoms of dry eye disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-masked, vehicle-controlled, phase 2 study evaluating the efficacy and&#xD;
      safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term&#xD;
      treatment of signs and symptoms of Dry Eye Disease (DED). The subjects will be followed for&#xD;
      approximately 2-3 months from screening to the last visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of bulbar conjunctival hyperemia from baseline by central reading center photographic assessment</measure>
    <time_frame>15 days post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>OTX-DED 0.2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 50 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OTX-DED 0.3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 50 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrogel Vehicle (HV)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 50 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-DED</intervention_name>
    <description>0.2mg dexamethasone ophthalmic insert</description>
    <arm_group_label>OTX-DED 0.2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-DED</intervention_name>
    <description>0.3mg dexamethasone ophthalmic insert</description>
    <arm_group_label>OTX-DED 0.3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-DED</intervention_name>
    <description>Hydrogel vehicle ophthalmic insert</description>
    <arm_group_label>Hydrogel Vehicle (HV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dry Eye Disease diagnosis&#xD;
&#xD;
          -  VAS eye dryness severity score â‰¥ 40.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are unwilling to discontinue use of contact lenses&#xD;
&#xD;
          -  Are unwilling to withhold use of artificial tears.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>781-357-4000</phone>
    <email>clinicalaffairs@ocutx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ocular Therapeutix</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dexamethasone ophthalmic insert</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

